# Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP

> **NCT00374998** · PHASE1 · COMPLETED · sponsor: **European Vaccine Initiative** · enrollment: 35 (—)

## Conditions studied

- Malaria, Falciparum
- Malaria

## Interventions

- **BIOLOGICAL:** FP9-PP (FP9 polyprotein)
- **BIOLOGICAL:** MVA-PP (Modified Virus Ankara polyprotein)

## Key facts

- **NCT ID:** NCT00374998
- **Lead sponsor:** European Vaccine Initiative
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 35 (—)
- **Last updated:** 2007-03-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00374998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00374998, "Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00374998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*